EU Patent Decision Admissible In Yaz Row, Bayer Says

Law360, New York (August 10, 2011, 1:01 PM EDT) -- Bayer Schering Pharma AG urged a Nevada federal judge on Tuesday to reject Lupin Ltd.'s objection to its use of a European Patent Office decision as evidence in its lawsuit over Lupin's efforts to launch a generic version of the birth control pill Yaz.

Bayer filed the suit in July 2010, claiming that Lupin infringed three of its patents for the birth control pill by submitting an abbreviated new drug application with the U.S. Food and Drug Administration seeking approval to market a generic version of...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.